The effects of ibopamine on cardiovascular and renal function in normal human subjects

Published

Journal Article

Ibopamine, a dopamine derivative, was administered orally to eight normal male subjects for the purpose of investigating the effects of this agent on cardiovascular and renal function. A double-blind, placebo-controlled, randomized, sequential-dosing design was utilized. Placebo or ibopamine in doses of 100, 200 and 300 mg were randomly given as a single dose to every subject on each of four successive. Supine and upright heart rate and systemic blood pressure did not change significantly after ibopamine. The systolic time interval measurements of inotropy, pre-ejection period index, and the pre-ejection period to left ventricular ejection time ratio improved significantly up to one hour and five to six hours after the 200-mg and 300-mg doses when compared to placebo. The duration of electromechanical systole (QS2I) was not altered by ibopamine. The echocardiographic parameters of ventricular function were not significantly different among the four treatment groups. Creatinine clearance tended to increase (p = 0.10) in a dose-dependent manner during the first two hours after ibopamine. Ibopamine did not significantly alter urine volume or sodium and potassium excretion. Ibopamine possesses positive inotropic properties and demonstrates favorable effects on renal function; it merits further investigation in states of cardiac failure.

Duke Authors

Cited Authors

  • Ren, JH; Leithe, ME; Huss, P

Published Date

  • January 1, 1983

Published In

Volume / Issue

  • 34 / 4 I

Start / End Page

  • 667 - 675

International Standard Serial Number (ISSN)

  • 0011-393X

Citation Source

  • Scopus